This paper is a review of the changes that have occurred over the past 35 years in the clinical and radiologic presentation of bronchopulmonary dysplasia (BPD), now more commonly referred to as chronic lung disease of infancy (CLD). Curent thoughts on etiology are only briefly discussed. The major focus is the management of the patient with CLD by the primary care physician once the patient has been discharged from hospital. Oxygen, diuretic, bronchodilator, antiinflammatory and nutritional therapies are discussed in detail. Finally, current information on long-term prognosis and recommendations for the prevention of RSV and influenza infections are reviewed.
Get full access to this article
View all access options for this article.
References
1.
1. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of membrane disease. N Engl J Med. 1967;276:357-368.
2.
2. Pusey VA, Macpherson RI, Chernick V. Pulmonary fibroplasia following prolonged artificial ventilation of the newborn infant. Can Med Assoc J1969;100:451-457.
3.
3 Bancalari E, Abdenour GE, Feller R, et al. Bronchopulmonary dysplasia: clinical presentation. J Pediatr1979;95:819-823.
4.
4. Shennan AT, Dunn MS, Ohlsonn A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82:527-532.
5.
5. Barrington KJ, Finer NN. Treatment of bronchopulmonary dysplasia. Clin Perinatol. 1998;25:177-202.
6.
6. Farrell PA, Fiascone JM. Bronchopulmonary dysplasia in the 1990s: a review for the pediatrician. Curr Probl Pe diatr. 1997;27:133-163.
7.
7. Ehrenkranz RA, Walsh-Sukys MC, Vohr BR, et al. New consensus definition of bronchopulmonary dysplasia (BPD-DEF) predicts pulmonary and neurodevelopemental outcomes in early infancy. Pediatr Res2001;49: 276A-276A.
8.
8. Jobe AH, Bancalari E. NICHD/ NHLBI/ORF workshop summary: bronchopulmonary dysplasia. Am J Respir Crit Car Med. 2001;163:1723-1729.
9.
9. Phillips AGS. Oxygen plus pressure plus time: the etiology of bronchopulmonary dysplasia. Pediatrics. 1975; 55:44-50.
10.
10. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999;46:641-643.
12. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Pediatr Clin a Vorth Am. 1994;41:277-315.
13.
13. Jobe AH. Influence of surfactant replacement on development of bronchopulmonary dysplasia. In: Bland RD, Coalson JJ, eds. Chronic Lung Disease in Early Infancy. New York: Marcel Dekker, Inc: 1999:237-256.
14.
14. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. J Clin Invest. 1995;95: 1798-1807.
15.
15. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial grown factor mRNA by the RNA binding protein HuR. J Biol Chem1998;273:6417-6423.
16.
16. Berman W Jr, Katz R, Yabek SM, et al. Long-term follow-tip of bronchopulmonary dysplasia. J Pediatr. 1986; 109:45-50.
17.
17. Groothius JR, Rosenberg AA. Home oxygen promotes weight gain in infants with bronchopulmonary dysplasia. Am J Dis Child. 1987;141:992-995.
18.
18. Poets CF, Southall DP. Noninvasive monitoring of oxygenation in infants and children: practical considerations and areas of concern. Pediatrics. 1994;93:737-746.
19.
19. Walsh MC, Noble LM, Carlo WA, Martin RJ. Relationship of pulse oximetry to arterial oxygen tension in infants. Crit Care Med. 1987; 1 5:1102-1105.
20.
20. Hazinski T. Drug treatment of established BPD. In: Bland RD, Coalson UJ, eds. Chronic Lung Disease in Early Infancy. New York: Marcel Dekker, Inc; 1999:257-283.
21.
21. Fan L, Voyles JB. Determination of inspired oxygen delivered by nasal cannula in infants with chronic lung disease. J Pediatr. 1983;103:923-925.
22.
22. Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr1989;115:615-620.
23.
23. Kao LC, Durand DJ, McCrea RC, et al. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr1994;124:772-781.
24.
24. Engelhardt B, Elliott S, Hazinski TA. Short and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia. J Pediatr. 1986;109:1034-1039.
25.
25. Kao LC, Warburton D, Cheng M, et al. Effect of oral diuretics on pulmonary mechanics in infants with bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics. 1984;74:37-44.
26.
26. Engelhardt B, Blalock WA, Donlevy S, et al. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic BPD. J Pediatr1989;114:619-624.
27.
27. Rastogi A, Luayon M, Ajayi OA, Pildes RS. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr1994;125:976-979.
29. Karlowicz MG, Katz ME, Adelman RD, Solhaug MJ. Nephrocalcinosis in very-low-birth-weight neonates: family history of kidney stones and ethnicity as independent risk factors. J Pediatr. 1993;122:635-638.
30.
30. Downing GJ, Egelhoff JC, Daily DK, et al. Kidney function in very-low-birth-weight infants with furosemide-related renal calcifications at ages 1 to 2 years. J Pediatr1992;120:599-604.
31.
31. Katz ME, Karlowicz MG, Adelman RD, et al. Nephrocalcinosis in very-low-birth-weight neonates: sonographic patterns, histologic characteristics, and clinical risk factors. J Ultrasound Med. 1994;13:777-782.
32.
32. Rush MG, Hazinski TA. Current therapy of bronchopulmonary dysplasia. Clin Perinatol. 1992;19:563-590.
33.
33. DeBoeck K, Smith J, Van Lierde S, Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. J Pediatr1998;157:75-79.
34.
34. Chambers HM, van Velzen D. Ventilator-related pathology in the extremely immature lung. Pathology. 1989;21:79-83.
35.
35. Downing GS, Kilbride HW. Evaluation of airway complications in high-risk pre-term infants: application of flexible fiberoptic airway endoscopy. Pediatrics. 1995;95:567-572.
36.
36. Panitch HB, Esteban N, Keklikian EN, et al. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol. 1990;9:170-176.
37.
37. Davis GM, Nguyen HN, Faucher D. Respiratory responses to salbutamol and dexamethazone in BPD. Am J Respir Crit Care Med. 1996;153:170-176.
38.
38. Kari MA, Heinonen K, Ikonen RS, et al. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Arch Dis Child. 1993;68:566-569.
39.
39. Papile L, Stoll B, Donovan E, et al. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): a multi-center randomized, double-masked trial. Pediatr Res. 1996;39: 236A-236A.
40.
40. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics. 1991;88:421-427.
41.
41. Rastogi A, Akintorin SM, Bez ML, et al. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996;98:204-210.
42.
42. Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethonase treatment in extremely low birth weight infants. N Engl J Med. 2001;344:945-1001.
43.
43. Watterberg KL, Murphy S. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: a pilot study. Pediatrics. 1993;91:803-806.
44.
44. Jacob SV, Coates AL, Lands LC, et al. Long-term pulmonary sequelae of severe bronchopulmonary dysplasia. J Pediatr. 1998;133:193-200.
45.
45. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol. 1995;19:371-378.
46.
46. Groneck P, Gotze-Speer B, Oppermann M, et al. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk neonates. Pediatrics. 1994;93:712-718.
47.
47. Yoon BH, Romero R, Jun JK, et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol. 1997;177:825-830.
48.
48. Munshi UK, Niu Jo, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from pre-term infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol. 1997;24:331-336.
49.
49. Frank L. Antioxidants, nutrition, and bronchopulmonary dysplasia. Clin Perinatol. 1992;19:541-562.
50.
50. Ehrenkranz RA, Ablow RC, Warshaw JB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann NY Acad Sci. 1982;393:452-466.
51.
51. Shenai JP, Kennedy KA, Chytil F. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987;111:269-277.
52.
52. Hallman M, Bry K, Hoppu K, et al. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med. 1992;326:1233-1239.
53.
53. Pereira GR, Baumgart S. Bennett MJ, et al. Use of high-fat formula for premature infants with bronchopulmonary dysplasia: metabolic, pulmonary, and nutritional studies. J Pediatr1994;124:605-611.
54.
54. Chessex P, Belanger S, Piedboeuf B, Pineault M. Influence of energy substrates on respiratory gas exchange during conventional mechanical ventilation of pre-term infants. J Pediatr1995;126:619-624.
55.
55. Billeaud C, Piedboeuf B, Chessex P. Energy expenditure and severity of respiratory disease in very-low-birth-weight infants receiving long-term ventilatory support. J Pediatr. 1992;120:461-464.
56.
56. Northway WH, Moss RB, Carlisle KB, et al. Late sequela of bronchopulmonary dysplasia. N Engl J Med. 1990;323:1793-1799.
57.
57. Andreasson B, Lindroth M, Mortensson W, et al. Lung function eight years after neonatal ventilation. Arch Dis Child. 1989;64:108-113.
58.
58. Kim YC, Wheeler W, Longmate J. Longitudinal study of lung function in children following bronchopulmonary dysplasia. Am Rev Respir Dis. 1988;137:A18-A18.
59.
59. Chernick V. Long-term pulmonary function studies in children with bronchopulmonary dysplasia: an ever-changing saga. Editorial. J Pediatr. 1998;133:171-172.
60.
60. Gross SJ, Januzzi DM, Kveselis DA, Anbar RD. Effect of pre-term birth on pulmonary function at school age: a prospective controlled study. J Pediatr1998;133:188-192.
61.
61. Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RS-IGIV. Pediatrics. 1998;102:1211-1216.
62.
62. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices. MMWR. 2001;50(RR04):1-48.
63.
63. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health. 2000;36:422-427.
64.
64. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical Trials. Pediatrics. 1990;86:728-736.
65.
65. Rojas MA, Gonzales A, Bancalari E, et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995; 126:605-610.
66.
66. Lee SK, McMillan DD, Ohlsonn A, et al. Variations in practice and outcomes in the Canadian NICU network 1996-1997. Pediatrics. 2000;106:1070-1079.
